Risk-Based Care
Helping patients with cancer and rare disease overcome barriers to treatment and increase time on therapy
Risk-Based Care breaks down barriers to medication adherence
Risk-Based Care is a personalized healthcare approach that uses a nurse/patient relationship to create a tailored care plan for each patient. In the Risk-Based Care model, a pharmacist first conducts a risk assessment to identify barriers to medication adherence.
Based on these results, a nurse is assigned to help implement tactics that address each patient’s individual barriers.
With the vast amount of information that can be shared during a medical appointment, it may be difficult for patients to remember all the important details of the visit, which may lead to medication errors or non-adherence. Regular check-ins with a nurse can help clarify any questions the patient has and address barriers to treatment.
In fact, recent research from Biologics and a third-party vendor, showed that cancer patients who were enrolled in the Risk-Based Care program stayed on therapy nearly two months longer than patients without care plans.¹
1 Biologics and Arine clinical research 2022
Risk-Based Care: Personalized Care for Better Patient Outcomes
Risk-based care by the numbers
MONTHS
+1.82 months on treatment
Cancer patients with Risk-Based Care plans stayed on therapy for significantly longer periods than patients without care plans and were at lower risk of discontinuing treatment.
Source: Biologics and Arine, 2022
3x less likely to report disease progression
Biologics patients who participated in Risk-Based Care were three times less likely to report disease progression than high‑risk patients who didn’t participate.
Source: Biologics, 2021
%
35% reduction in reported hospitalizations
The reduction in the rate of reported hospitalizations when patients received personalized support through Risk-Based Care
Source: Biologics, 2021
MONTHS
+1.82 months on treatment
Cancer patients with Risk-Based Care plans stayed on therapy for significantly longer periods than patients without care plans and were at lower risk of discontinuing treatment.
Source: Biologics and Arine, 2022
3x less likely to report disease progression
Biologics patients who participated in Risk-Based Care were three times less likely to report disease progression than high‑risk patients who didn’t participate.
Source: Biologics, 2021
%
35% reduction in reported hospitalizations
The reduction in the rate of reported hospitalizations when patients received personalized support through Risk-Based Care
Source: Biologics, 2021
Patient Voice Spotlight: Dan W.
Meet Dan W., a leukemia survivor who called his Biologics nurse his “guardian angel.” For him, she was a lifeline at a very scary time.
Frequently asked questions
How does Risk-Based Care work?
Risk-Based Care customizes support to meet the unique needs of individual patients on specific therapies, rather than a larger patient population. It helps clinicians get to the root cause of specific struggles that patients experience, which helps patients stay on track with therapy as prescribed.
How does the Risk-Based Care model help patients?
The Risk-Based Care model is especially helpful for patients who are identified as being at high risk for medication nonadherence. The Risk-Based Care model recognizes that everyone who takes a particular medication does not need the same type of support or frequency of engagement with a clinician.
How does Biologics’ Risk-Based Care program support providers?
Our Risk-Based Care program closely models the type of care that patients receive in face-to-face clinical settings, where they’re supported by familiar providers who know the particulars of their situation. This care model recognizes that patients need continual, consistent, and individualized support at a level that’s appropriate for them throughout the treatment journey.
BLOG
Discover how Biologics by McKesson helps patients stay on therapies longer with risk-based care.
Want to learn more?
We’re here to help—contact us or browse career opportunities.